Syneos Health (SYNH) Lowered to Hold at Zacks Investment Research
Zacks Investment Research lowered shares of Syneos Health (NASDAQ:SYNH) from a buy rating to a hold rating in a research note released on Saturday morning.
According to Zacks, “INC Research Holdings, Inc. is a global contract research organization. It provides the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. Its services include clinical trial management services comprising patient recruitment and retention, project management, clinical monitoring, drug safety/pharmacovigilance, medical affairs, quality assurance, regulatory and medical writing, and functional service; and data services consisting of clinical data management, electronic data capture, and biostatistics. INC Research Holdings, Inc. is headquartered in Raleigh, North Carolina. “
SYNH has been the topic of a number of other reports. Evercore ISI initiated coverage on shares of Syneos Health in a research note on Thursday, October 4th. They set an outperform rating and a $58.00 price target on the stock. UBS Group initiated coverage on shares of Syneos Health in a research note on Tuesday, October 9th. They set a buy rating and a $60.00 target price on the stock. SunTrust Banks restated a buy rating and set a $60.00 target price on shares of Syneos Health in a research note on Friday, August 3rd. William Blair upgraded shares of Syneos Health from a market perform rating to an outperform rating in a research note on Friday, October 19th. Finally, KeyCorp upped their target price on shares of Syneos Health from $54.00 to $59.00 and gave the stock an overweight rating in a research note on Friday, August 10th. Two equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus target price of $54.70.
Syneos Health (NASDAQ:SYNH) last issued its quarterly earnings results on Tuesday, November 6th. The company reported $0.75 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.58 by $0.17. The company had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.12 billion. Syneos Health had a negative net margin of 0.84% and a positive return on equity of 8.67%. Syneos Health’s revenue for the quarter was up 88.3% compared to the same quarter last year. Analysts anticipate that Syneos Health will post 2.47 EPS for the current fiscal year.
Several hedge funds have recently added to or reduced their stakes in SYNH. First Manhattan Co. purchased a new stake in shares of Syneos Health during the third quarter worth approximately $103,000. LPL Financial LLC acquired a new position in Syneos Health in the first quarter valued at approximately $236,000. First Trust Advisors LP acquired a new position in Syneos Health in the second quarter valued at approximately $241,000. BB&T Corp acquired a new position in Syneos Health in the second quarter valued at approximately $244,000. Finally, Crossmark Global Holdings Inc. acquired a new position in Syneos Health in the second quarter valued at approximately $246,000.
About Syneos Health
Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as unbundled service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.